PDCD1 and neoplasm: Amplification of chromosome 9p24.19 and activation of AP-110 by HRS cells result in increased expression of PD-L1 and/or PD-L2, and interaction of these ligands with PD-1 + effector T cells inhibits an effective anti-tumor immune response.